Form 4: Anebulo Pharmaceuticals Director Acquires Stock Options

Nathaniel Calloway, a director of Anebulo Pharmaceuticals, acquired stock options on April 4, 2025.

Summary

• On April 4, 2025, Nathaniel Calloway, a director at Anebulo Pharmaceuticals, acquired stock options.
• He obtained options to purchase 25,000 shares and 3,309 shares of common stock at an exercise price of $1.02.
• The options vest on the earlier of April 4, 2026, or the date of the 2026 annual meeting of shareholders and expire on April 3, 2035.
• Following the transaction, Calloway directly owns options for 28,309 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance, but rather provides transparency into insider ownership.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the director.

Key Dates

Keywords

stock options, director, ANEB, Anebulo Pharmaceuticals, Form 4, Calloway, insider trading